Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2.
about
Exogenous administration of protease-resistant, non-matrix-binding IGFBP-2 inhibits tumour growth in a murine model of breast cancer.Dual targeting of the type 1 insulin-like growth factor receptor and its ligands as an effective antiangiogenic strategyCan we unlock the potential of IGF-1R inhibition in cancer therapy?Differential regulation of orphan nuclear receptor TR3 transcript variants by novel vascular growth factor signaling pathways.A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma.A new bispecific antibody targeting non-overlapping epitopes on IGF2: design, in vitro characterization and pharmacokinetics in macaquesThe role of the insulin-like growth factor-1 system in breast cancerHighly specific role of the insulin receptor in breast cancer progression.The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link.Targeted therapy in sarcomas other than GIST tumorsInhibition of intracerebral glioblastoma growth by targeting the insulin-like growth factor 1 receptor involves different context-dependent mechanisms.STAT3-mediated IGF-2 secretion in the tumour microenvironment elicits innate resistance to anti-IGF-1R antibodyRidaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood SarcomaA dual-specific anti-IGF-1/IGF-2 human monoclonal antibody alone and in combination with temsirolimus for therapy of neuroblastoma.Emblica officinalis extract downregulates pro-angiogenic molecules via upregulation of cellular and exosomal miR-375 in human ovarian cancer cellsIdentification of RSK and TTK as Modulators of Blood Vessel Morphogenesis Using an Embryonic Stem Cell-Based Vascular Differentiation AssayRole of Phosphorylated HDAC4 in Stroke-Induced Angiogenesis.Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales.Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference.Immunotherapy for the treatment of colorectal tumors: focus on approved and in-clinical-trial monoclonal antibodies.Endurance Exercise Improves Molecular Pathways of Aerobic Metabolism in Patients With Myositis.Antibody-based therapeutics against components of the IGF system.Tumour growth stimulation following partial hepatectomy in mice is associated with increased upregulation of c-Met.Comparison of Non-human Primate versus Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Treatment of Myocardial Infarction.
P2860
Q30384833-99F6B2C4-1C98-4162-8453-99161D2EF3ADQ30540343-AABB9284-794B-45D1-A58A-38D650FB9E1BQ34336988-50AC6568-1F26-4C1B-A180-3DC2861238ABQ34365504-1E4DC676-B2F0-4E67-B7F9-C3807ACE7DA9Q34532397-49F7936C-84FB-45AA-AA52-96E6AD9E446FQ34674197-451AD28F-30B4-473D-B949-00B654781026Q35105295-09E98887-C7E8-477E-A26C-ECA33D6D786FQ35185029-040DFA6E-FE43-453B-9F66-4711D3849AA4Q35609517-62643292-934F-4871-B8E8-0400B520E4E7Q35622367-5A552252-8CA0-43B0-8912-7B256CB4F134Q35815279-1F80B52E-A51E-49DF-8C89-E0203A34276DQ36169762-0CDD82B0-B60B-435E-BF30-1B49251A5FFAQ36169793-395A6789-9C77-4A97-BE8C-3B908EE936F8Q36615766-B0D40643-5559-49F6-9937-EC8068C93774Q36918007-366455DD-7B98-406F-B51C-D60250AC8925Q37162205-CBBBDD04-FC55-4EC0-B4DD-066BCA20C3C9Q37327795-22211910-F9A6-49E5-8F5D-4416305CED5BQ37338152-D19BED26-490C-400E-AEF3-1475A9305FA2Q37588724-4F1E25F2-68A2-4D07-BE0E-EC83D01C4026Q38130312-0085C6B9-4D6F-408F-8249-A6A34938475BQ38259982-A6B170DF-01A5-4162-BEC5-46B96BDDA956Q39110385-D4630284-EDC8-4545-9C25-824301718D05Q40004698-1CBBF8D1-62A1-4BE5-B17B-3D0BD7A9B273Q42142138-2C7DA15B-EA41-42E2-AEA4-E75B287319BEQ44408938-3A0A357B-108C-4FC3-953F-AC9F63EE3525Q49341169-460892A3-81D0-490B-9685-C83004386DD3
P2860
Potent inhibition of angiogenesis by the IGF-1 receptor-targeting antibody SCH717454 is reversed by IGF-2.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Potent inhibition of angiogene ...... CH717454 is reversed by IGF-2.
@ast
Potent inhibition of angiogene ...... CH717454 is reversed by IGF-2.
@en
type
label
Potent inhibition of angiogene ...... CH717454 is reversed by IGF-2.
@ast
Potent inhibition of angiogene ...... CH717454 is reversed by IGF-2.
@en
prefLabel
Potent inhibition of angiogene ...... CH717454 is reversed by IGF-2.
@ast
Potent inhibition of angiogene ...... CH717454 is reversed by IGF-2.
@en
P2093
P2860
P1476
Potent inhibition of angiogene ...... CH717454 is reversed by IGF-2.
@en
P2093
Doris A Phelps
Hemant K Bid
Peter J Houghton
Raushan T Kurmasheva
P2860
P304
P356
10.1158/1535-7163.MCT-11-0575
P577
2011-12-21T00:00:00Z